胰高血糖素样肽-1受体激动剂使用与白内障发生风险
这项回顾性队列研究基于TriNetX全球协作网络,纳入55岁及以上超重或肥胖的非糖尿病患者,比较使用GLP-1RA(司美格鲁肽或利拉鲁肽)与其他减重药物(OWLD)或未用药者发生年龄相关性白内障的风险。结果显示,与OWLD相比,GLP-1RA使用者在5年、7年和10年的年龄相关性白内障风险均降低;与未用药者相比,GLP-1RA使用者的风险也降低,而OWLD使用者的风险则升高。
要点
- 在超重或肥胖的非糖尿病55岁及以上人群中,GLP-1RA使用与5年、7年和10年年龄相关性白内障风险降低相关。
- 与未用药者相比,GLP-1RA使用者在5年、7年和10年的年龄相关性白内障风险也降低。
- 与未用药者相比,OWLD使用者在5年、7年和10年的年龄相关性白内障风险升高。
核心结论
- 与OWLD使用和未接受药物治疗相比,GLP-1RA使用与年龄相关性白内障风险显著降低相关。
- 作者认为这些发现支持需要开展随机前瞻性试验和机制研究,以更好地理解这一观察到的关联。
研究设计与样本
- 回顾性队列研究,使用TriNetX全球协作网络数据。
- 纳入55岁及以上超重或肥胖患者,排除糖尿病或既往年龄相关性白内障患者。
- GLP-1RA组使用司美格鲁肽或利拉鲁肽;OWLD组使用氯卡色林、司美拉诺肽、二乙丙胺、西布曲明、芬氟拉明、马吲哚、芬特明或奥利司他;第三队列为未使用任何减重药物的患者。
- 采用倾向性评分匹配以最小化队列间基线差异。
- 主要结局为5年、7年和10年时年龄相关性白内障的发生,报告风险比(RR)及其95%置信区间(CI)和P值,并计算标准化均数差(SMD)评估协变量平衡。
主要发现
- 在GLP-1RA与OWLD的主要分析中,所有匹配变量的SMD均<0.2,协变量平衡达标。
- 与OWLD使用相比,GLP-1RA使用与5年(RR:0.278;95%CI:0.246-0.314;P<.0001)、7年(RR:0.269;95%CI:0.241-0.299;P<.0001)和10年(RR:0.198;95%CI:0.176-0.222;P<.0001)年龄相关性白内障风险降低相关。
- 与未用药相比,GLP-1RA使用与5年(RR:0.605;95%CI:0.553-0.661;P<.0001)、7年(RR:0.499;95%CI:0.458-0.542;P<.0001)和10年(RR:0.437;95%CI:0.403-0.475;P<.0001)年龄相关性白内障风险降低相关。
- 与未用药相比,OWLD使用与5年(RR:2.142;95%CI:1.957-2.345;P<.0001)、7年(RR:2.093;95%CI:1.931-2.268;P<.0001)和10年(RR:2.111;95%CI:1.961-2.273;P<.0001)年龄相关性白内障风险升高相关。
局限性
- 作者在结论中提出这些发现支持需要开展随机前瞻性试验和机制研究,以更好地理解这一观察到的关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the risk of developing age-related cataract among nondiabetic patients who are overweight or obese prescribed glucagon-like peptide-1 receptor agonists (GLP-1RAs) compared to other weight loss drugs (OWLD). DESIGN: Retrospective cohort study using the TriNetX Global Collaborative Network. SUBJECTS: Overweight or obese patients aged 55 years and greater were included. Patients with a diabetes mellitus or prior age-related cataract were excluded. METHODS: Patients in the GLP-1RA group were prescribed either semaglutide or liraglutide. Patients in the OWLD group were lorcaserin, setmelanotide, diethylpropion, sibutramine, fenfluramine, mazindol, phentermine, or orlistat A third cohort included patients not prescribed any weight loss medications. Propensity score matching was performed to minimize baseline differences between cohorts. MAIN OUTCOME MEASURES: The primary outcome was development of age-related cataract at 5-, 7-, and 10-year intervals. Risk ratios with 95% confidence intervals and corresponding P-values were reported. Standardized mean differences (SMDs) were calculated to assess covariate balance. RESULTS: In the primary analysis of GLP-1RA vs OWLD usage, covariate balance was achieved across all matched variables with SMDs < 0.2. In this primary analysis, GLP-1RA use was associated with a decreased risk of age-related cataract at 5 (RR: 0.278; 95% CI: 0.246-0.314; P < .0001), 7 (RR: 0.269; 95% CI: 0.241-0.299; P < .0001), and 10 (RR: 0.198; 95% CI: 0.176-0.222; P < .0001) years compared to OWLD use. GLP-1RA use was also associated with decreased risk at 5 (RR: 0.605; 95% CI: 0.553-0.661; P < .0001), 7 (RR: 0.499; 95% CI: 0.458-0.542; P < .0001), and 10 (RR: 0.437; 95% CI: 0.403-0.475; P < .0001) years compared to no drug use. Conversely, OWLD use was associated with increased risk at 5 (RR: 2.142; 95% CI: 1.957-2.345; P < .0001), 7 (RR: 2.093; 95% CI: 1.931-2.268; P < .0001) and 10 (RR: 2.111; 95% CI: 1.961-2.273; P < .0001) years compared to no drug use. CONCLUSIONS: GLP-1RA use was associated with a significantly reduced risk of age-related cataract compared to OWLD use and no pharmacologic treatment. These findings support the need for randomized prospective trials and mechanistic studies to better understand this observed association.
引用
- Ahuja AS, Paredes AA, Ahuja SA, et al. Glucagon-like Peptide-1 Receptor Agonist Use and Risk of Cataract Development. Am J Ophthalmol. 2025. PMID: 41130371. doi:10.1016/j.ajo.2025.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。